High caffeine consumption / nicotine (historical association).
Clinical Features
Cyclic Mastalgia:
Bilateral, diffuse, poorly localized; most prominent in upper outer quadrants (UOQ).
Starts during the luteal phase (premenstrual), peaks before menses, resolves with onset of menses. c
Sensation described as dull, heavy, or aching; mild diffuse nodularity on PE without discrete mass.
Noncyclic Mastalgia:
Unilateral, localized/focal, sharp or burning quality.
Constant or intermittent; no relationship to menstrual cycle.
Physical Examination (PE):
Palpation: Check for focal masses, discrete cysts, warmth, fluctuance, or skin tethering.
Nipple evaluation: Spontaneous vs expressible discharge, inversion, skin retraction.
Lymph nodes: Palpate axillary, supraclavicular, and infraclavicular chains.
Chest wall: Palpate costochondral junctions and pectoralis major to evaluate for costochondritis (reproducible tenderness).
Diagnosis
Step 1: Clinical Triage & Risk Stratification:
Exclude pregnancy: Urine β-hCG if reproductive age with new-onset symptoms.
Determine if pain is cyclic vs noncyclic, diffuse vs focal, and presence vs absence of palpable mass.
Step 2: Imaging Algorithm (Guided by age and PE findings):
Cyclic, diffuse pain + Normal PE:
No imaging needed (reassurance and symptomatic management). c
Focal pain OR Palpable Mass:
Age < 30: Targeted Breast Ultrasound (US).
Age ≥ 30: Diagnostic Mammography (MMG) + Targeted Breast Ultrasound (US).
Confirmatory / Tissue Sampling:
Core Needle Biopsy (CNB): Indicated if imaging identifies a suspicious lesion (BI-RADS 4 or 5).
Fine-Needle Aspiration (FNA): Indicated for symptomatic, painful simple or complex cysts.
Differential Diagnostics
Fibrocystic Changes:
The timing of the pain cycle is same with cyclic mastalgia c
Diffuse, bilateral cyclic pain with multiple fluctuating breast lumps/nodularity; diff by cyclic size fluctuation and improvement after menses.
Costochondritis (Tietze Syndrome):
Extramammary pain; diff by focal chest wall tenderness reproducible on palpation over costosternal junctions.
Mastitis / Breast Abscess:
Lactating females; diff by systemic symptoms (fever, chills), localized warmth, erythema, and fluctuant mass (abscess on US).
Inflammatory Breast Cancer (IBC):
Diff by rapid onset (< 6 months) of breast erythema, edema, peau d’orange, axillary LAD, and nipple retraction (mimics mastitis but fails to improve with antibiotics).
Fat Necrosis:
Diff by history of breast trauma, biopsy, or radiation; presents as painless or tender mass with oil cysts or coarse calcifications on imaging.
Fibroadenoma:
Diff by well-circumscribed, firm, mobile (“breast mouse”), non-tender or minimally tender discrete mass.
Management
First-Line / Conservative:
Reassurance: Confirm absence of malignancy on exam/imaging (resolves symptoms in >80% of pts).
Mechanical support: Well-fitted, supportive bra (especially during exercise).
Analgesia: Topical or oral NSAIDs / acetaminophen.
Medication adjustment: Lower estrogen dose in OCPs/HRT or transition to non-hormonal contraception.
Second-Line / Severe Refractory (Intractable cyclic pain > 6 months):
Tamoxifen (SERM, off-label): Highly effective, but risk of hot flashes, VTE, and endometrial hyperplasia.
Danazol (Androgen agonist, only FDA-approved agent): Effective, but limited by androgenic adverse effects (acne, hirsutism, voice deepening, weight gain).
Invasive / Etiology-Specific:
Cyst aspiration: For painful, tense macrocysts.
Incision & Drainage (or needle aspiration) + Abx: For breast abscess.
Complications
Significant anxiety and cancer-related fear (cancer phobia).
Impairment of daily activities and sexual function.
Medication adverse effects (virilization from Danazol, thromboembolic events from Tamoxifen).
Delay in diagnosis of underlying malignancy if noncyclic focal pain is inappropriately dismissed.